Drug Trial Radar · NCT02871492
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Last checked: Nov 19, 2026Latest source record: Jul 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
362
Actual
Start
Nov 29, 2016
Primary completion
Sep 29, 2017
Study completion Oct 16, 2017
Sponsor
- Lead sponsor
- AiCuris Anti-infective Cures AGIndustry
- Sponsor type
- Industry
- Collaborators
- Novella Clinical
- First posted
- Aug 18, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent herpes labialis (RHL) in comparison with placebo or Zovirax® Cream. The start of treatment with trial medication will be initiated by the subject within one hour of noticing the first sign or symptom (eg, prodrome) of a recurrence of herpes labialis. Trial medication will be applied to the affected area 5 times daily for 4 days. After self-initiation of treatment with trial medication subjects will be assessed daily by the Investigator until complete healing for a maximum of 13 days. Subjects will document application of trial medication and the status of their lesion in a diary. There will also be blood sampling, ECG measurement and physical examination performed at the investigational site.
Conditions
- Herpes Labialis
Interventions
Pritelivir 5% w/w ointmentDrug
Pritelivir ointment matching placeboDrug
Zovirax® creamDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's AssessmentTime frame: 13 days
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Scottsdale, Arizona
Site not named
Santa Rosa, California
Site not named
Pinellas Park, Florida
Site not named
Edina, Minnesota
Site not named
St Louis, Missouri
Site not named
Akron, Ohio
Site not named
Cincinnati, Ohio
Site not named
Anderson, South Carolina
Site not named
Greer, South Carolina
Site not named
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.